



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 38002-0024

Applicant(s): David MU et al.

Confirmation No.: 2406

Serial No.: 10/073,060

Examiner: To be assigned

Filing Date: February 12, 2002

Group Art Unit: 1645

Title: AMPLIFIED CANCER GENE HEPSIN

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

Applicants believe that the instant Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits under 37 CFR §1.97(b)(3), therefore, no fee is required in connection with its filing.

RECEIVED

NOV 05 2002

TECH CENTER 1600/2900

U.S. Serial No. 10/073,060

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,



John P. Isacson
Reg. No. 33,715

November 4, 2002
Date

HELLER EHRMAN WHITE & MCAULIFFE
1666 K Street, N.W., Suite 300
Washington, D.C. 20006
Phone: (202) 912-2000
Fax: (202) 912-2020



26633

ATTY DOCKET NO.
38002-0024SERIAL NO.
10/073,060LIST OF REFERENCES CITED
BY APPLICANT(S)APPLICANT(S)
David MU et al.

Date Submitted: November 4, 2002

FILING DATE
February 12, 2002GROUP
1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE (M/D/Y)	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE (M/D/Y)	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	C01	WO91/09974	7/11/91	WIPO		
	C02	WO99/00504	1/7/99	WIPO		
	C03	WO99/44063	9/2/99	WIPO		
	C04	WO02/50247	6/27/02	WIPO		

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

C05	TANIMOTO et al.	Proceedings of the American Assoc. for Cancer Research, Vol. 38, pg. 413, Abstract XP002938744 (1997)
C06	TANIMOTO et al.	Journal of the Society for Gynecologic Investigation 4(1): 577, Abstract XP002938745 (1977)
C07		Serine Protease Hepsin (HEPS_HUMAN), retrieved from EBI Database Acession No. P05981, Abstract XP002213746 (1988)
C08		Serine Protease Hepsin (human) mRNA, retrieved from EBI Database Acession No. AI289181, Abstract XP002213747 (1988)

RECEIVED

NOV 05 2002

EXAMINER

DATE CONSIDERED

TECH CENTER 1600/2900